The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter Langmuir
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Finsen Centre National Hospital
Copenhagen, Denmark
- Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
- Istituto Nazionale Tumori Regina Elena Irccs
Rome, Italy
- Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte
Siena, Italy
- Kanagawa Cancer Center
Yokohama, Japan
- John Wayne Cancer Institute
Santa Monica, California, United States
- Oncology Specialists of Charlotte
Charlotte, North Carolina, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- South Texas Accelerated Research Therapeutics
San Antonio, Texas, United States
- Virginia Cancer Specialists, Pc
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 Jul 2021
- Primary completion
- 11 Apr 2024
- Completion
- 11 Apr 2024
- Last update posted
- 19 Sept 2024
- Registered enrollment
- 10
- Registry id
- NCT04949191
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.